Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) ended Thursday session in green amid volatile trading. The shares closed up +4.46 points or 13.07% at $38.58 with 4.35 million shares getting traded. Post opening the session at $34.94, the shares hit an intraday low of $34.90 and an intraday high of $38.98 and the price vacillated in this range throughout the day. The company has a market cap of $1.05 billion and the numbers of outstanding shares have been calculated to be 29.19 million shares.
Aerie Pharmaceuticals Inc (AERI) on September 16, 2016 announced the pricing of a registered underwritten public offering of $75 million of shares of its common stock at a price to the public of $29.50 per share, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering was upsized by $25 million over the offering amount anticipated to be sold as previously announced. This is in addition to $50 million raised separately through the completion and full utilization of an at-the-market (ATM) program with Cantor Fitzgerald & Co. filed prior to market open on September 15, 2016. Total gross proceeds raised through these offerings were $125 million. The shares sold through the $50 million ATM program will be issued on or about September 20, 2016, and the $75 million public offering is expected to close on or about September 21, 2016, subject to the satisfaction of customary closing conditions.
Shares of Boston Scientific Corporation (NYSE:BSX) ended Thursday session in red amid volatile trading. The shares closed down -0.20 points or -0.85% at $23.31 with 12.08 million shares getting traded. Post opening the session at $23.73, the shares hit an intraday low of $23.26 and an intraday high of $23.76 and the price vacillated in this range throughout the day. The company has a market cap of $31.73 billion and the numbers of outstanding shares have been calculated to be 1.36 billion shares.
Boston Scientific Corporation (BSX) on Sept. 19, 2016 received CE Mark for the LOTUS Edge™ Valve System, the company’s next generation transcatheter aortic valve implantation (TAVI) technology. The LOTUS Edge valve system is indicated for aortic valve replacement in patients with severe aortic stenosis who are considered at high risk for surgical valve replacement. Instead of open heart surgery, the replacement valve is delivered via transcatheter percutaneous delivery, a minimally invasive procedure involving a small incision to gain access to a blood vessel.
In comparison to the Lotus™ Valve System, this next iteration incorporates a more flexible, lower profile catheter designed to improve ease of use and accommodate tortuous anatomy. Another differentiating feature of the LOTUS Edge valve system is the inclusion of Depth Guard™, a design element intended to reduce the need for a permanent pacemaker (PPM).
“The LOTUS Edge device is a highly anticipated next generation of the Lotus Valve System,” said Professor Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia. “It retains many of its predecessor’s unique and valuable proprietary features, including the ability to reposition the device precisely and prevent paravalvular leak, while incorporating new design characteristics such as a more flexible catheter for easier delivery and Depth Guard™ technology designed to reduce valve interaction with the conduction system of the heart during valve deployment.”